Transvaginal administration of progesterone

  • Bicêtre Hospital ROR
  • Université de Versailles Saint-Quentin-en-Yvelines ROR
  • Hôpital Antoine-Béclère ROR

Obstetrics and Gynecology, 90(3), 396-401

DOI 10.1016/s0029-7844(97)00270-6 PMID 9277651

Abstract

Objective

To examine the endometrial effects of three different doses of progesterone administered vaginally.

Methods

Forty women 25-41 years old deprived of ovarian function received estradiol (E2) for 28 days. From days 15 to 27, a new mucus-like vaginal gel of progesterone was administered every other day, randomly, dosed at 45 mg (group A, n = 14), 90 mg (group B, n = 13), or 180 mg (group C, n = 13). Plasma gonadotropins, estrone, E2, and progesterone were measured. An endometrial biopsy was performed on day 20 (n = 20) or 24 (n = 20) for endometrial dating and for estrogen and progesterone receptor determinations.

Results

Plasma estrogen levels were in the menstrual cycle range. Mean progesterone levels were lower in group A (2.4 +/- 0.2 ng/mL) than in group B (3.6 +/- 0.2 ng/mL) or C (3.4 +/- 0.4 ng/mL) (P < .005). Plasma FSH and LH decreased significantly during progesterone treatment. In all groups, we observed secretory transformation in the glands (day 20) and stroma (day 24) and the distribution of estrogen and progesterone receptors seen in normal menstrual cycles.

Conclusion

Transvaginal administration of progesterone induced normal secretory transformation of the endometrium despite low plasma levels, suggesting a direct transit into the uterus or "first uterine pass effect."

Topics

transvaginal progesterone gel endometrial secretory transformation, vaginal progesterone first uterine pass effect, Fanchin de Ziegler vaginal progesterone endometrium, progesterone vaginal gel dose response endometrial biopsy, low plasma progesterone adequate endometrial transformation vaginal, estrogen progesterone receptor endometrium vaginal progesterone, vaginal progesterone 45 90 180 mg endometrial dating, transvaginal progesterone administration luteal phase support, uterine first pass effect progesterone vaginal gel, endometrial secretory transformation progesterone receptor distribution
PMID 9277651 9277651 DOI 10.1016/s0029-7844(97)00270-6 10.1016/s0029-7844(97)00270-6

Cite this article

Fanchin, R., De Ziegler, D., Bergeron, C., Righini, C., Torrisi, C., & Frydman, R. (1997). Transvaginal administration of progesterone. *Obstetrics and gynecology*, *90*(3), 396-401. https://doi.org/10.1016/s0029-7844(97)00270-6

Related articles